≡

Complement Component 9 (C9)

[Edit]

Complement Component 9 (C9)
CCC B823
HGNC 1358
MGI 1098282
PubMed 22796422
RGD 620319
UniProt P02748
Wiki C9

Activation of the complement system results in formation of the membrane attack complex (MAC) on the membranes of target cells. The complex is assembled by sequential addition of 1 molecule each of C5b, C6, C7, and C8 and 6 to 16 molecules of the ninth component, C9.

DiScipio et al. (1984) screened a human liver cDNA library by the colony-hybridization technique using 2 radiolabelled oligonucleotide probes that correspond to known regions of the C9 amino acid sequence. The cDNA coding for C9 was sequenced and the protein sequence--537 amino acids in a single polypeptide chain--was derived. The amino-terminal half of C9 is predominantly hydrophilic and the carboxyl-terminal half is more hydrophobic.

Organism species: Homo sapiens (Human)

CATALOG NO. PRODUCT NAME APPLICATIONS
Proteins RPB823Hu01 Recombinant Complement Component 9 (C9) Positive Control; Immunogen; SDS-PAGE; WB.
CPB823Hu21 OVA Conjugated Complement Component 9 (C9) Immunogen; SDS-PAGE; WB.
APB823Hu01 Active Complement Component 9 (C9) Cell culture; Activity Assays.
Antibodies PAB823Hu01 Polyclonal Antibody to Complement Component 9 (C9) WB; IHC; ICC; IP.
MAB823Hu22 Monoclonal Antibody to Complement Component 9 (C9) WB; IHC; ICC; IP.
PAB823Hu08 Polyclonal Antibody to Complement Component 9 (C9) WB; IHC; ICC; IP.
Assay Kits SEB823Hu ELISA Kit for Complement Component 9 (C9) Enzyme-linked immunosorbent assay for Antigen Detection.

Organism species: Mus musculus (Mouse)

CATALOG NO. PRODUCT NAME APPLICATIONS
Proteins RPB823Mu01 Recombinant Complement Component 9 (C9) Positive Control; Immunogen; SDS-PAGE; WB.
Antibodies PAB823Mu01 Polyclonal Antibody to Complement Component 9 (C9) WB; IHC; ICC; IP.
Assay Kits SEB823Mu ELISA Kit for Complement Component 9 (C9) Enzyme-linked immunosorbent assay for Antigen Detection.

Organism species: Rattus norvegicus (Rat)

CATALOG NO. PRODUCT NAME APPLICATIONS
Proteins RPB823Ra01 Recombinant Complement Component 9 (C9) Positive Control; Immunogen; SDS-PAGE; WB.
Antibodies PAB823Ra01 Polyclonal Antibody to Complement Component 9 (C9) WB; IHC; ICC; IP.
Assay Kits n/a CLIA Kit for Complement Component 9 (C9) CLIA Kit Customized Service Offer
n/a ELISA Kit for Complement Component 9 (C9) ELISA Kit Customized Service Offer

Organism species: Oryctolagus cuniculus (Rabbit)

CATALOG NO. PRODUCT NAME APPLICATIONS
Proteins RPB823Rb01 Recombinant Complement Component 9 (C9) Positive Control; Immunogen; SDS-PAGE; WB.
Antibodies PAB823Rb51 Polyclonal Antibody to Complement Component 9 (C9) WB,IHC
PAB823Rb01 Polyclonal Antibody to Complement Component 9 (C9) WB; IHC; ICC; IP.
Assay Kits n/a CLIA Kit for Complement Component 9 (C9) CLIA Kit Customized Service Offer
n/a ELISA Kit for Complement Component 9 (C9) ELISA Kit Customized Service Offer
  1. "The sequence and topology of human complement component C9."EMBO J. 4:375-382(1985) [PubMed] [Europe PMC] [Abstract]
  2. "The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)."Genome Res. 14:2121-2127(2004) [PubMed] [Europe PMC] [Abstract]
  3. "Nucleotide sequence of cDNA and derived amino acid sequence of human complement component C9."Proc. Natl. Acad. Sci. U.S.A. 81:7298-7302(1984) [PubMed] [Europe PMC] [Abstract]
  4. "Relationships between the gene and protein structure in human complement component C9."Biochemistry 27:6529-6534(1988) [PubMed] [Europe PMC] [Abstract]
  5. "Heterogeneity in the genetic basis of human complement C9 deficiency."Immunogenetics 48:144-147(1998) [PubMed] [Europe PMC] [Abstract]
  6. "The architecture of complement component C9 and poly(C9)."J. Biol. Chem. 260:14802-14809(1985) [PubMed] [Europe PMC] [Abstract]
  7. "Identification of disulfide bonds in the ninth component (C9) of human complement."FEBS Lett. 380:8-12(1996) [PubMed] [Europe PMC] [Abstract]
  8. "The four terminal components of the complement system are C-mannosylated on multiple tryptophan residues."J. Biol. Chem. 274:32786-32794(1999) [PubMed] [Europe PMC] [Abstract]
  9. "Screening for N-glycosylated proteins by liquid chromatography mass spectrometry."Proteomics 4:454-465(2004) [PubMed] [Europe PMC] [Abstract]
  10. "Human plasma N-glycoproteome analysis by immunoaffinity subtraction, hydrazide chemistry, and mass spectrometry."J. Proteome Res. 4:2070-2080(2005) [PubMed] [Europe PMC] [Abstract]
  11. "Elucidation of N-glycosylation sites on human platelet proteins: a glycoproteomic approach."Mol. Cell. Proteomics 5:226-233(2006) [PubMed] [Europe PMC] [Abstract]
  12. "Glycoproteomics analysis of human liver tissue by combination of multiple enzyme digestion and hydrazide chemistry."J. Proteome Res. 8:651-661(2009) [PubMed] [Europe PMC] [Abstract]
  13. "A strategy for precise and large scale identification of core fucosylated glycoproteins."Mol. Cell. Proteomics 8:913-923(2009) [PubMed] [Europe PMC] [Abstract]
  14. "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome."J. Proteomics 96:253-262(2014) [PubMed] [Europe PMC] [Abstract]
  15. "Localization and molecular modelling of the membrane-inserted domain of the ninth component of human complement and perforin."Mol. Immunol. 27:589-602(1990) [PubMed] [Europe PMC] [Abstract]
  16. "Rare variants in CFI, C3 and C9 are associated with high risk of advanced age-related macular degeneration."Nat. Genet. 45:1366-1370(2013) [PubMed] [Europe PMC] [Abstract]